HB 0017

1
A bill to be entitled
2An act relating to developmental disabilities; amending s.
3409.912, F.S.; requiring the Agency for Health Care
4Administration to develop a model waiver program to serve
5children with specified disorders; requiring the agency to
6seek federal waiver approval and implement the approved
7waiver subject to availability of funds and certain
8limitations; authorizing rules; providing an effective
9date.
10
11Be It Enacted by the Legislature of the State of Florida:
12
13     Section 1.  Subsection (50) is added to section 409.912,
14Florida Statutes, to read:
15     409.912  Cost-effective purchasing of health care.--The
16agency shall purchase goods and services for Medicaid recipients
17in the most cost-effective manner consistent with the delivery
18of quality medical care. To ensure that medical services are
19effectively utilized, the agency may, in any case, require a
20confirmation or second physician's opinion of the correct
21diagnosis for purposes of authorizing future services under the
22Medicaid program. This section does not restrict access to
23emergency services or poststabilization care services as defined
24in 42 C.F.R. part 438.114. Such confirmation or second opinion
25shall be rendered in a manner approved by the agency. The agency
26shall maximize the use of prepaid per capita and prepaid
27aggregate fixed-sum basis services when appropriate and other
28alternative service delivery and reimbursement methodologies,
29including competitive bidding pursuant to s. 287.057, designed
30to facilitate the cost-effective purchase of a case-managed
31continuum of care. The agency shall also require providers to
32minimize the exposure of recipients to the need for acute
33inpatient, custodial, and other institutional care and the
34inappropriate or unnecessary use of high-cost services. The
35agency may mandate prior authorization, drug therapy management,
36or disease management participation for certain populations of
37Medicaid beneficiaries, certain drug classes, or particular
38drugs to prevent fraud, abuse, overuse, and possible dangerous
39drug interactions. The Pharmaceutical and Therapeutics Committee
40shall make recommendations to the agency on drugs for which
41prior authorization is required. The agency shall inform the
42Pharmaceutical and Therapeutics Committee of its decisions
43regarding drugs subject to prior authorization. The agency is
44authorized to limit the entities it contracts with or enrolls as
45Medicaid providers by developing a provider network through
46provider credentialing. The agency may limit its network based
47on the assessment of beneficiary access to care, provider
48availability, provider quality standards, time and distance
49standards for access to care, the cultural competence of the
50provider network, demographic characteristics of Medicaid
51beneficiaries, practice and provider-to-beneficiary standards,
52appointment wait times, beneficiary use of services, provider
53turnover, provider profiling, provider licensure history,
54previous program integrity investigations and findings, peer
55review, provider Medicaid policy and billing compliance records,
56clinical and medical record audits, and other factors. Providers
57shall not be entitled to enrollment in the Medicaid provider
58network. The agency is authorized to seek federal waivers
59necessary to implement this policy.
60     (50)  The agency shall work with the Department of Children
61and Family Services to develop a model home and community-based
62waiver to serve children who are diagnosed with familial
63dysautonomia or Riley-Day syndrome caused by a mutation of the
64IKBKAP gene on chromosome 9. The agency shall seek federal
65waiver approval and implement the approved waiver subject to the
66availability of funds and any limitations provided in the
67General Appropriations Act. The agency may adopt rules to
68implement this waiver program.
69     Section 2.  This act shall take effect July 1, 2005.


CODING: Words stricken are deletions; words underlined are additions.